Quretech Bio

QureTech Bio is a preclinical-stage biotech tackling the global crisis of antimicrobial resistance (AMR) with a novel antivirulence strategy. The company's proprietary GmPcide compounds aim to disarm pathogenic bacteria by inhibiting key virulence mechanisms, potentially rendering resistant bacteria susceptible again to existing antibiotics. Founded on academic research from Umeå University, the company is building a portfolio supported by recent US patents and Swedish Research Council funding. Leadership combines deep scientific expertise in microbiology and chemistry with seasoned biotech industry experience.

Small molecule antivirulence platform (GmPcides) targeting bacterial protein-protein interactions to disarm pathogens and restore antibiotic susceptibility.

The competitive landscape includes large pharma with antibiotic divisions (e.g., Merck, Pfizer) and numerous biotechs developing both traditional and novel-mechanism antibiotics. QureTech differentiates via its specific focus on small-molecule inhibition of virulence PPIs, a niche with fewer clinical-stage competitors compared to direct-kill mechanisms.